Treatment of relapsed ovarian carcinoma is still a matter of controversy. One important question to be solved is the potential superiority of combination chemotherapy over single-agent chemotherapy. This is a field in which a nonconclusive small number of randomized clinical trials have been conducted, and therefore, definitive conclusions are lacking. Patients with recurrent platinum-resistant disease are better treated with sequential single agent, because of higher toxicity without clear benefit usually associated with combination chemotherapy. In patients with platinum-sensitive disease, we can choose between three options: single-agent carboplatin, single-agent new drug or platinum combination-based therapy. In this paper, we will review these options and recently closed or ongoing randomized clinical trials in this setting.